Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (DE:HDP1)
FRANKFURT:HDP1
RESEARCH TOOLSreports
Holding DE:HDP1?
Track your performance easily
HDP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€15.94 - €36.69
Previous Close€18.62
Volume0.00
Average Volume (3M)70.00
Market Cap
€2.33B
Enterprise Value€2.27B
Total Cash (Recent Filing)$578.28M
Total Debt (Recent Filing)$510.55M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Feb 05, 2025EPS Estimate
-€0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.61
Shares Outstanding124,434,442
10 Day Avg. Volume5
30 Day Avg. Volume70
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)12.49
Price to Sales (P/S)123.17
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue638.48
Enterprise Value/Gross Profit638.48
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
€39.37Price Target Upside111.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Development And ApprovalPlozasiran's best-in-class characteristics on efficacy, quarterly dosing, and side effect profile make it well-positioned to become the standard-of-care in FCS if approved.
Financial Stability And PartnershipsThe partnership with SRPT provides a significant cash infusion of over $1.1 billion, strengthening the company's balance sheet for future milestones.
Research And Development ProgressThe company's R&D engine continues to show productivity, generating compelling next or best-in-class programs.
Bears Say
Business DevelopmentArrowhead announced it will not pursue further development of ARO-MUC5AC due to the inability to reliably assess the primary target engagement biomarker.
Capital MarketThe cardiovascular outcomes trial is on hold awaiting visibility on additional capital.
Financial PerformanceThe recent equity sell-off was driven by relatively expensive debt financing and higher than expected R&D spending, which increased manufacturing and clinical trial costs.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.58% Insiders
20.72% Mutual Funds
23.22% Other Institutional Investors
26.02% Public Companies and
Individual Investors
HDP1 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was €15.94 and its highest was €36.69 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Feb 05, 2025 which is in 45 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Nov 26, 2024. The company reported -€1.295 earnings per share for the quarter, missing the consensus estimate of -€1.066 by -€0.229.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -€0.39.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 124,434,440 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -€1.295 in its last earnings report, missing expectations of -€1.066. Following the earnings report the stock price went up 13.065%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 95M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€39.37 (111.48% Upside)
€39.37 (111.48% Upside)
Blogger Sentiment
Bullish
DE:HDP1 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.11%
12-Months-Change
Fundamentals
Return on Equity
-262.48%
Trailing 12-Months
Asset Growth
48.89%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
HDP1 Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong focus on strategic growth and clinical advancements for Arrowhead, particularly through plozasiran's promising results and pipeline expansion. However, financial challenges remain with increased losses and R&D expenses, balanced by strategic financing efforts.Read More>---
HDP1 Stock 12 Month Forecast
Average Price Target
€39.37
▲(111.48% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Voyager Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering HDP1
1 Year
1 Year Success Rate
19/39 ratings generated profit
1 Year Average Return
+30.47%
reiterated a buy rating 11 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 48.72% of your transactions generating a profit, with an average return of +30.47% per trade.
---